NCT02242227View on ClinicalTrials.gov

Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder Administered Via the HandiHaler® 2 and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

February 28, 2006

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Salmeterol xinafoate

DRUG

Serevent® Diskus®

DRUG

Placebo (HandiHaler®)

DRUG

Placebo (Diskus®)

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02242227 - Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder Administered Via the HandiHaler® 2 and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter